A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

• Status: RECRUITING
• Trial end date: 2030-08-01

Summary

The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

• Phase: PHASE2

Details

• Lead Sponsor: Jazz Pharmaceuticals
• Collaborator: Jazz Pharmaceuticals Ireland Limited
• Treatments: Carboplatin; Docetaxel; Paclitaxel; pertuzumab; Trastuzumab; zanidatamab